JP2013523680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523680A5 JP2013523680A5 JP2013501789A JP2013501789A JP2013523680A5 JP 2013523680 A5 JP2013523680 A5 JP 2013523680A5 JP 2013501789 A JP2013501789 A JP 2013501789A JP 2013501789 A JP2013501789 A JP 2013501789A JP 2013523680 A5 JP2013523680 A5 JP 2013523680A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino
- trifluoromethyl
- hydroxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014426.6 | 2010-04-01 | ||
| DE102010014426A DE102010014426A1 (de) | 2010-04-01 | 2010-04-01 | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| PCT/EP2011/054733 WO2011120922A1 (de) | 2010-04-01 | 2011-03-28 | Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523680A JP2013523680A (ja) | 2013-06-17 |
| JP2013523680A5 true JP2013523680A5 (https=) | 2014-05-15 |
| JP5816259B2 JP5816259B2 (ja) | 2015-11-18 |
Family
ID=43858236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501789A Expired - Fee Related JP5816259B2 (ja) | 2010-04-01 | 2011-03-28 | 腫瘍治療用の新規なｐａｎ−ＣＤＫ阻害剤の使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130210846A1 (https=) |
| EP (1) | EP2552450A1 (https=) |
| JP (1) | JP5816259B2 (https=) |
| KR (1) | KR20130014678A (https=) |
| CN (1) | CN102834100A (https=) |
| AU (1) | AU2011234654B2 (https=) |
| BR (1) | BR112012024422A2 (https=) |
| CA (1) | CA2794996A1 (https=) |
| CL (1) | CL2012002753A1 (https=) |
| CR (1) | CR20120502A (https=) |
| DE (1) | DE102010014426A1 (https=) |
| DO (1) | DOP2012000260A (https=) |
| EC (1) | ECSP12012198A (https=) |
| MA (1) | MA34098B1 (https=) |
| MX (1) | MX337722B (https=) |
| NZ (1) | NZ602710A (https=) |
| PH (1) | PH12012501945A1 (https=) |
| SG (2) | SG183925A1 (https=) |
| TN (1) | TN2012000469A1 (https=) |
| UA (1) | UA108494C2 (https=) |
| WO (1) | WO2011120922A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2867746A1 (en) * | 2012-03-21 | 2013-09-26 | Bayer Intellectual Property Gmbh | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours |
| CN105007945A (zh) * | 2013-03-07 | 2015-10-28 | 拜耳医药股份有限公司 | (rs)-s-环丙基-s-(4-{[4-{[(1r,2r)-2-羟基-1-甲基丙基]氧基}-5-(三氟甲基)嘧啶-2-基]氨基}苯基)亚砜亚胺用于治疗特定肿瘤的用途 |
| WO2014160130A1 (en) * | 2013-03-13 | 2014-10-02 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| WO2014173815A1 (en) * | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
| JP2016526540A (ja) * | 2013-06-21 | 2016-09-05 | バイエル ファーマ アクチエンゲゼルシャフト | 置換ベンジルピラゾール |
| WO2015071231A1 (de) * | 2013-11-14 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren |
| CN109283279B (zh) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法 |
| CN109283263B (zh) * | 2017-07-21 | 2019-06-25 | 南京正大天晴制药有限公司 | 用于雷替曲塞合成质量控制的检测分析方法 |
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
| AU744986B2 (en) | 1997-07-12 | 2002-03-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6632820B1 (en) | 1998-08-29 | 2003-10-14 | Astrazeneca Ab | Pyrimidine compounds |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| KR100874791B1 (ko) | 2001-05-29 | 2008-12-18 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도 |
| AU2003212282A1 (en) | 2002-03-11 | 2003-09-22 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
| DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| DE102006027156A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| EP1878726A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| EP2179991A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2010
- 2010-04-01 DE DE102010014426A patent/DE102010014426A1/de not_active Withdrawn
-
2011
- 2011-03-28 CA CA2794996A patent/CA2794996A1/en not_active Abandoned
- 2011-03-28 NZ NZ602710A patent/NZ602710A/en not_active IP Right Cessation
- 2011-03-28 UA UAA201212233A patent/UA108494C2/uk unknown
- 2011-03-28 EP EP11710224A patent/EP2552450A1/de not_active Withdrawn
- 2011-03-28 PH PH1/2012/501945A patent/PH12012501945A1/en unknown
- 2011-03-28 SG SG2012065819A patent/SG183925A1/en unknown
- 2011-03-28 US US13/638,833 patent/US20130210846A1/en not_active Abandoned
- 2011-03-28 WO PCT/EP2011/054733 patent/WO2011120922A1/de not_active Ceased
- 2011-03-28 JP JP2013501789A patent/JP5816259B2/ja not_active Expired - Fee Related
- 2011-03-28 BR BR112012024422A patent/BR112012024422A2/pt not_active IP Right Cessation
- 2011-03-28 KR KR1020127025684A patent/KR20130014678A/ko not_active Ceased
- 2011-03-28 SG SG10201502566SA patent/SG10201502566SA/en unknown
- 2011-03-28 AU AU2011234654A patent/AU2011234654B2/en not_active Ceased
- 2011-03-28 MA MA35265A patent/MA34098B1/fr unknown
- 2011-03-28 MX MX2012011427A patent/MX337722B/es active IP Right Grant
- 2011-03-28 CN CN2011800166124A patent/CN102834100A/zh active Pending
-
2012
- 2012-09-27 TN TNP2012000469A patent/TN2012000469A1/en unknown
- 2012-10-01 CL CL2012002753A patent/CL2012002753A1/es unknown
- 2012-10-01 CR CR20120502A patent/CR20120502A/es unknown
- 2012-10-01 EC ECSP12012198 patent/ECSP12012198A/es unknown
- 2012-10-01 DO DO2012000260A patent/DOP2012000260A/es unknown